

THIS ANNOUNCEMENT IS NOT INTENDED FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS FORBIDDEN UNDER APPLICABLE LAW.

UCB successfully completes its offer to the public of fixed rate notes and decides to early terminate the subscription period

Brussels (Belgium), 9 November 2023 – 6 p.m. (CET) – Regulated Information

On 7 November 2023, UCB SA/NV (“**UCB**”) announced the issuance, by way of an offer to the public in Belgium and Luxembourg under its recently updated Euro Medium Term Note program, of 5.20% fixed rate notes with a maturity of 6 years for a minimum amount of EUR 100 million and a maximum amount of EUR 300 million (the “**Notes**”). The subscription period for the issue started on 9 November 2023.


As the maximum amount of EUR 300 million has been raised entirely, UCB has decided to terminate the subscription period early on 9 November 2023 at 5:30 p.m. (CET).

The Notes (ISIN BE0002976570) will be issued on 21 November 2023 and an application has been made for the Notes to be listed on Euronext Brussels and to be admitted to trading on the regulated market of Euronext Brussels as from the issue date. The expected payment date is 21 November 2023.

In light of the oversubscription of the offer, a reduction will apply. This means that the subscriptions will be scaled back proportionally, with an allocation of a multiple of EUR 1,000 and, to the extent possible (i.e., to the extent there are not more investors than Notes), a minimum nominal amount of EUR 1,000 which corresponds to the denomination of the Notes and is the minimum subscription amount for investors. Subscribers may have different reduction percentages applied in respect of the amounts subscribed by them depending on the financial intermediary through which they have subscribed to the Notes. The subscribers will be notified of the number of Notes allotted to them by the applicable financial intermediary as soon as possible.

The proceeds of this issue will be used for general corporate and financing purposes of the Issuer and its subsidiaries, including the partial refinancing of outstanding bank term loans.

Sandrine Dufour, CFO UCB commented: “We are very pleased with the confidence retail investors have shown in us through their positive response to this notes issuance. The success of this transaction underlines UCB’s access to diversified funding sources and allows us to extend our debt maturity profile.”



UCB News

This message should be read in conjunction with the base prospectus dated 17 October 2023, as supplemented by the supplement n°1 dated 24 October 2023, and the final terms relating to the Notes, which includes the issue-specific summary in English, Dutch and French. These documents are available on the websites of [UCB](#), Belfius Bank ([NL/FR](#)), BNP Paribas Fortis ([NL/FR](#)), ING Bank N.V., Belgian Branch ([NL/FR](#)) and KBC Bank ([NL/FR](#)).



Disclaimer

THIS ANNOUNCEMENT IS NOT INTENDED FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS FORBIDDEN UNDER APPLICABLE LAW.

This announcement does not constitute an offer to sell or to subscribe to securities, or an invitation to make an offer to purchase securities or to subscribe to securities, and securities shall not be sold or subscribed to in any jurisdiction in which such offer, invitation, sale or subscription would be illegal without prior subscription or qualification under the financial legislation of such jurisdiction. The issue of, subscription to or purchase of securities is subject to special statutory or regulatory restrictions in certain jurisdictions. UCB is not liable in the event of any violation of such restrictions by any person.

No public offering of any securities referred to in this document shall be made in the United States. The securities referred to in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") or the securities law of any State or any jurisdiction in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from the registration requirements of the Securities Act. Terms used in this paragraph have the meanings given to them by Regulation S under the Securities Act. The securities referred to in this document have not been approved or disapproved by the SEC, any other State securities commission or any other supervisory body of the United States, nor have these authorities assessed the adequacy of this proposed offering or the adequacy or accuracy of this document. Any representation to the contrary is a criminal offence in the United States.

This document is not an offering document or prospectus in connection with an offering of securities by UCB. Investors must not accept any offering of the securities referred to in this document nor acquire them unless they do so on the basis of information contained in the base prospectus dated 17 October 2023, as supplemented by the supplement n°1 dated 24 October 2023, and the final terms relating to the Notes.



UCB News

For questions on this press release or for further information, contact UCB:

Investor Relations

Antje Witte

T +32 2 559 94 14

antje.witte@ucb.com

Julien Bayet

T +32 2 559 95 80

julien.bayet@ucb.com

Corporate Communications

Laurent Schots

T+32 2 559 92 64

laurent.schots@ucb.com





UCB News

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8,700 people in approximately 40 countries, the company generated revenue of €5.5 billion in 2022 UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

